Endo low-T drug Aveed wins FDA OK; black box, restricted distribution vexes investors
This article was originally published in Scrip
Executive Summary
While Endo Pharmaceuticals' win from the US FDA for the firm’s hypogonadism drug Aveed (testosterone undecanoate) should have had investors cheering, they likely were scared off by the black-box warning imposed on the medicine’s labeling.